Dr. Jun Ho Kim
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
At a glance
- In the NPI registry since
- 2014
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
FL license ME134715 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 4 companies reported 15 payments worth $10,756 in total to this clinician.
| Sarepta Therapeutics, Inc. | $8,845 |
|---|---|
| Biogen, Inc. | $1,655 |
| F. Hoffmann-la Roche AG | $150 |
| Genentech, Inc. | $105 |
| Consulting Fee | $8,563 |
|---|---|
| Travel and Lodging | $1,641 |
| Food and Beverage | $552 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sarepta Therapeutics, Inc. Jul 29, 2025 | Consulting Fee Elevidys · Genetic Disease | $7,055 |
| Biogen, Inc. Mar 19, 2025 | Consulting Fee | $1,508 |
| Sarepta Therapeutics, Inc. Jul 18, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Washington, DC · in-kind | $670 |
| Sarepta Therapeutics, Inc. Jul 18, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Washington, DC · in-kind | $386 |
| Sarepta Therapeutics, Inc. Jul 19, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Washington, DC · in-kind | $373 |
| Sarepta Therapeutics, Inc. Aug 13, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Washington, DC · in-kind | $118 |
| Sarepta Therapeutics, Inc. Aug 13, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Washington, DC · in-kind | $70.94 |
| Sarepta Therapeutics, Inc. Aug 13, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Washington, DC · in-kind | $22.66 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $81,661 in research payments for these studies, mostly to the institutions running them.
- A phase ii study of satralizumab in pediatric patients with duchenne muscular dystrophy
Genentech, Inc. - Risdiplam post gene therapy study plateau symptoms study 2
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.